Naomi C. Sacks

Naomi C. Sacks

Auto-generated profile, based on publicly available information

Naomi C. Sacks

HEORStrategies Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2021 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
MRMichael Rehorn
Michael Rehorn
NSNaomi C. Sacks
Naomi C. Sacks
MEMaia R. Emden
Maia R. Emden
BHBridget Healey
Bridget Healey
MPMadison T. Preib
Madison T. Preib
SPSean D. Pokorney
Sean D. Pokorney

6 October 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
NSNaomi C. Sacks
Naomi C. Sacks
KEKatie Everson
Katie Everson
MEMaia R. Emden
Maia R. Emden
PCPhillip L. Cyr
Phillip L. Cyr
DWDavid R. Wood
David R. Wood
SPSean D. Pokorney
Sean D. Pokorney
Background: Information on differences in paroxysmal supraventricular tachycardia (PSVT) diagnosis, healthcare resource use, expenditures, and treatment among women versus men is limited. Methods and Results: Study participants identified in the IBM MarketScan Commercial Research Databases were aged 18 to 40 years with newly diagnosed PSVT ( International Classification of Diseases, Ninth Revision [ ICD‐9 ]: 427.0; International Classification of Diseases, Tenth Revision [ ICD‐10 ]: I47.1) from October 1, 2012, through September 30, 2016, observable 1 year preindex and postindex diagnosis. Study outcomes were mean annual per‐patient healthcare resource use and expenditures before and after diagnosis. Among 5466 patients newly diagnosed with PSVT, most (66.9%) were women. Compared with men, women with PSVT tended to have higher rates of anxiety (13.9% versus 10.9%; P <0.01) and chronic pulmonary disease (10.9% versus 8.3%; P <0.01). Following diagnosis, mean annual per‐patient expenditures increased for all patients, but were significantly lower for women ($26 922 versus $33 112; P <0.05), reflecting lower spending for services billed as a result of a PSVT diagnosis ($8471 versus $11 405; P <0.05). After diagnosis, nearly half of all patients had at least 1 emergency department visit (women versus men, 49.6% versus 44.5%; P <0.01) and more had hospital admissions (women versus men, 24.7% versus 20.0%; P <0.01). Fewer women were treated with cardiac ablation (12.6% versus 15.3%; P <0.01), and more were treated with medical therapy, including β blockers or calcium channel blockers (odds ratio, 1.15; 95% CI, 1.02–1.31). Conclusions: Among patients aged 18 to 40 years, ≈2 of 3 patients diagnosed with PSVT were women. After diagnosis, spending was significantly lower for women, reflecting lower ablation rates and less spending on services with a PSVT diagnosis.

2 May 2022 in Clinical Therapeutics
Verified
Journal Article
Open access
ASAjay Sheshadri
Ajay Sheshadri
NSNaomi C. Sacks
Naomi C. Sacks
BHBridget E. Healey
Bridget E. Healey
SRSajjad Raza
Sajjad Raza
GBGerhard Boerner
Gerhard Boerner
HHHoward J Huang
Howard J Huang
Bronchiolitis obliterans syndrome (BOS) is a major cause of morbidity and mortality in lung transplantation and allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Clinical guidelines recommend lung function monitoring to aid early identification of BOS, but real-world rates of pulmonary function testing (PFT) have not been studied. The purpose of this study was to quantify PFT rates in lung transplantation and allo-HSCT recipients. This longitudinal retrospective study used US data from the IQVIA PharMetrics Plus commercial claims database (January 1, 2006-September 30, 2018) and the Medicare Limited Data Set (January 1, 2010-December 31, 2018). Study recipients had no evidence of transplantation 12 months before transplantation, which was identified by using diagnosis and procedure codes. PFTs were identified by using procedure codes. Outcomes were percentage of recipients who received ≥1 PFT in each follow-up year, including spirometry, lung diffusion capacity, lung function volume test, and plethysmography, including the average number of total and specific tests per recipient. The study identified 367 commercially insured and 1776 Medicare recipients who underwent lung transplantation; 92% and 86% received ≥1 lung function test in the first year after transplantation, respectively. Among recipients observable 3 years after transplant, 85% and 83% received ≥1 PFT. Among 2187 commercially insured and 1864 Medicare recipients who underwent allo-HSCT, 44% and 36% received ≥1 lung function test in the first posttransplant year. In the third year after transplant, only 31% and 26% of observable allo-HSCT recipients underwent any PFT. Morbidity and mortality from BOS remain high in lung transplant and allo-HSCT recipients, but lung function testing in the first posttransplant year is not universal, with substantially lower rates among allo-HSCT recipients. Furthermore, testing rates in all cohorts declined over time. Increased and sustained monitoring could lead to earlier detection of BOS and earlier intervention and treatment.

13 December 2023 in Obesity Science & Practice
Verified
Journal Article
Open access
JMJoanna P. MacEwan
Joanna P. MacEwan
KCKevin Chiu
Kevin Chiu
NANadia N. Ahmad
Nadia N. Ahmad
NSNaomi Sacks
Naomi Sacks
SSShraddha Shinde
Shraddha Shinde
HKHong Kan
Hong Kan
Objectives: This study aimed to estimate clinical, economic (including productivity), and health‐related quality of life (HRQoL) outcomes and associated individual characteristics among adults with overweight (OW) or obesity in the United States.Methods: This study included adult respondents with body mass index (BMI) ≥18.5 kg/m2 in the 2017–2018 National Health and Nutrition Examination Survey (NHANES) and 2016 Medical Expenditure Panel Survey. Respondents were classified according to BMI. Individual characteristics were described by BMI categories. Multivariable regression models estimated the association between BMI categories and outcomes, adjusting for individual characteristics.Results: Nearly three‐quarters (73.7%) of NHANES participants were OW or obese. Relative to Normal weight (NW), respondents with Class 3 obesity had more obesity‐related complications (2.07 vs. 4.62, p < 0.001). Higher BMI was associated with significantly lower HRQoL, lower productivity, and higher healthcare expenditures as well as more frequent weight loss attempts in the previous 12 months. Weight loss surgery and prescription anti‐obesity medications (AOMs) were used only by a very small proportion of individuals. Despite frequent weight loss attempts, most respondents did not achieve clinically meaningful weight loss.Conclusions: Adults with OW or obesity experienced worse clinical, economic and HRQoL outcomes than those with NW. Better use of evidence‐based obesity treatments, including prescription AOMs, should be considered to achieve more clinically meaningful weight reduction and improved outcomes in individuals with OW or obesity.

31 December 2022 in Journal of Medical Economics
Verified
Journal Article
Open access
ASAjay Sheshadri
Ajay Sheshadri
NSNaomi C. Sacks
Naomi C. Sacks
BHBridget Healey
Bridget Healey
PCPhil Cyr
Phil Cyr
GBGerhard Boerner
Gerhard Boerner
HHHoward J. Huang
Howard J. Huang
Aims Chronic lung allograft dysfunction (CLAD), a common complication of lung transplantation, is the leading cause of death for lung transplant recipients. While data on lung transplant costs are available, the impact of CLAD on healthcare resource use (HRU) and cost is not well understood. The primary objective was to quantify the HRU and costs of CLAD in the US using real-world data. Methods A longitudinal retrospective analysis was performed of commercial claims data from the IQVIA PharMetrics Plus database for patients aged 18-64 who underwent lung transplantation between January 1, 2006 and September 30, 2018. Lung transplantation was identified using International Classification of Disease and Common Procedure Terminology procedure codes. Patients studied were observable for at least 12 months before and after transplantation. Patients who developed CLAD were identified using novel, diagnosis codes for incident lung disease at least one year following transplantation. Descriptive analyses were conducted to assess the study's outcomes prior to and following a CLAD diagnosis. All-cause HRU and costs, the study's primary outcomes, leading up to and following CLAD diagnosis were calculated. Results Among 129 transplant patients who developed CLAD, healthcare costs were substantially higher in the year following diagnosis ($198,113), compared to the year leading to diagnosis ($85,276). Inpatient admissions were responsible for most costs in years 1 and 2 following diagnosis ($99,372 and $83,348 respectively). Drug costs were higher in the 12 months post-index, compared to the 12 months pre-index ($3,600 vs $2,527). Limitations Claims data do not include clinical data, have limits determining loss of follow-up, and do not provide granularity to determine disease severity. Also, there is no ICD-10-CM code specific to CLAD or BOS. Conclusions CLAD after lung transplant is associated with substantial HRU and costs. Further work is needed to develop interventions that reduce this impact.

12 April 2021 in Journal of Managed Care & Specialty Pharmacy
Verified
Journal Article
Open access
NSNaomi C Sacks
Naomi C Sacks
BHBridget E Healey
Bridget E Healey
PCPhilip L Cyr
Philip L Cyr
TSTheodore Slocomb
Theodore Slocomb
EJEmma James
Emma James
RGRobert J Graham
Robert J Graham
BACKGROUND: In X-linked myotubular myopathy (XLMTM), mutations in the MTM1 gene result in absence or dysfunction of myotubularin, a protein required for normal development, maintenance, and functio...